Maksymowych et al. assessed the frequency of axial spondyloarthritis (axSpA) according to extra-articular presentation and human leukocyte antigen B27 (HLA-B27) status and sought to identify features that distinguish patients with axSpA from those with non-specific back pain. Their data support recommendations that patients with chronic back pain and extra-articular features related to axSpA be screened for axSpA with MRI and referred to a rheumatologist.
Search results for: musculoskeletal disease
FDA Approves Bimekizumab-bkzx (Bimzelx) for 3 New Rheumatic Indications
The FDA has approved bimekizumab-bkzx for the treatment of adults with psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.
The Identification & Management of Hypophosphatasia
With the U.S. Food & Drug Administration’s approval in 2014 of asfotase alfa for replacement of tissue-non-specific alkaline phosphatase (TNSALP or TNAP) in juvenile-onset hypophosphatasia (HPP), rheumatologists have a responsibility to recognize the more subtle manifestations of this condition in adults to avoid missed treatment opportunities for fractures, dental loss and musculoskeletal pain. Hypophosphatasia is…
Top Research in Rheumatoid Arthritis Presented at ACR Convergence 2024
Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…
Are Sacroiliac Joint MRIs Accurate in Routine Clinical Practice?
Hadsbjerg et al. compared assessments of sacroiliac joint MRIs in local MRI reports from routine care in five European countries with re-reads by central experts in patients with a diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) to estimate the extent of over- or under-reporting of features and misclassification.
Top Research in Psoriatic Arthritis Presented at ACR Convergence 2024
Editor’s note: What research on psoriatic arthritis (PsA) presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. Dr. Pisetsky, a professor of medicine and immunology…
Precision Medicine Benefits Patients with Systemic Sclerosis
Experts provided insights into how precision medicine is being used to address the needs and care of patients with systemic sclerosis.
Should We Manage Men & Women Differently?
Experts address how sex differences affect the clinical presentation, diagnosis, response to therapy and experience of illness for patients with PsA.
Advancements in Imaging
Experts shared insights into their work on building consensus for the use of musculoskeletal ultrasound for the diagnosis and management of RA and PsA.
Approaches to Difficult-to-Manage Spondyloarthritis
At this ACR Convergence 2024 session, two experts spoke about identifying difficult-to-manage patients with spondyloarthritis, differentiating active disease from fibromyalgia & therapy selection in these patients.
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- …
- 96
- Next Page »